Vali A Papadimitrakopoulou

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Pilot randomized phase II study of celecoxib in oral premalignant lesions
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2095-101. 2008
  2. pmc Optimizing biomarkers and endpoints in oral cancer chemoprevention trials
    William N William
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:375-8. 2013
  3. doi request reprint Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer
    Vassiliki Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 7:1315-26. 2012
  4. doi request reprint Cyclin D1 and cancer development in laryngeal premalignancy patients
    Vassiliki Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:14-21. 2009
  5. pmc Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:599-604. 2009
  6. ncbi request reprint The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy
    Vassiliki Papadimitrakopoulou
    MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:749-51. 2006
  7. ncbi request reprint The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Lett 239:136-43. 2006
  8. ncbi request reprint Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors
    Vali Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:4151-9. 2005
  9. ncbi request reprint Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
    V A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Arch Otolaryngol Head Neck Surg 125:1083-9. 1999
  10. ncbi request reprint Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:1605-10. 2002

Detail Information

Publications31

  1. doi request reprint Pilot randomized phase II study of celecoxib in oral premalignant lesions
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2095-101. 2008
    ..In this pilot randomized phase II study, we evaluated the efficacy and safety of the COX-2 inhibitor celecoxib in patients with oral premalignant lesions (OPL)...
  2. pmc Optimizing biomarkers and endpoints in oral cancer chemoprevention trials
    William N William
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:375-8. 2013
    ..In this commentary, the complexities involved in defining optimal biomarkers and endpoints for oral cancer prevention trials and the development of dietary chemoprevention agents are discussed...
  3. doi request reprint Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer
    Vassiliki Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 7:1315-26. 2012
    ....
  4. doi request reprint Cyclin D1 and cancer development in laryngeal premalignancy patients
    Vassiliki Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:14-21. 2009
    ..04) and within each CD1 genotype group. These findings support CD1 genotype and protein expression as important risk markers for laryngeal cancer and suggest future trials targeting upstream regulators of CD1 transcription...
  5. pmc Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:599-604. 2009
    ....
  6. ncbi request reprint The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy
    Vassiliki Papadimitrakopoulou
    MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:749-51. 2006
    ..We review current information on the therapeutic manipulation of these targets and describe early clinical data in lung cancer...
  7. ncbi request reprint The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Lett 239:136-43. 2006
    ....
  8. ncbi request reprint Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors
    Vali Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:4151-9. 2005
    ....
  9. ncbi request reprint Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
    V A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Arch Otolaryngol Head Neck Surg 125:1083-9. 1999
    ....
  10. ncbi request reprint Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 11:1605-10. 2002
    ..o. cavity, a series of biomarkers extensively used in previous chemoprevention trials, including chromosome polysomy (CP), proliferative status, p53 expression and gene mutations, and loss of heterozygosity at 9p, 3p, and 17p...
  11. ncbi request reprint Chemoprevention of head and neck cancer: an update
    Vali A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 14:318-22. 2002
    ..Chemoprevention research is based on the increasing body of knowledge of the biology underlying head and neck tumorigenesis and is expected to ultimately result in a decrease in the incidence of head and neck cancer...
  12. ncbi request reprint Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development
    V A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1500 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 7:3127-34. 2001
    ....
  13. ncbi request reprint Carcinogenesis of head and neck cancer and the role of chemoprevention in its reversal
    V A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Curr Opin Oncol 12:240-5. 2000
    ..Newly acquired knowledge in the field of tumor biology and of the genetic changes underlying carcinogenesis through the use of new molecular technology represents the basis on which chemoprevention efforts should be based...
  14. doi request reprint Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy
    Gokcen Yildirim
    The University of Texas M D Anderson Cancer Center, Department of Radiation Oncology, Unit 97, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Head Neck 32:473-80. 2010
    ..Our aim was to evaluate the therapeutic outcomes of patients with squamous cell carcinoma of the tonsil that underwent tonsillectomies followed by radiotherapy...
  15. doi request reprint Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
    Invest New Drugs 29:499-505. 2011
    ..To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin...
  16. ncbi request reprint The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 95:340-53. 2002
    ..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC...
  17. ncbi request reprint Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
    George R Blumenschein
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Invest New Drugs 26:81-7. 2008
    ..Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients...
  18. ncbi request reprint Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment
    Ian J Bristol
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:719-30. 2007
    ..To determine the effects of three changes in radiotherapy technique on the outcomes for patients irradiated postoperatively for maxillary sinus cancer...
  19. ncbi request reprint Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer
    Faye M Johnson
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Lung Cancer 5:40-5. 2003
    ..With the exception of the 2 deaths, the therapy was well tolerated and active. Phase II evaluation of the regimen in patients with extensive-stage SCLC is ongoing...
  20. ncbi request reprint Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
    Ralph G Zinner
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:2449-56. 2005
    ..The primary objectives of this study were to determine the efficacy and tolerability of a pemetrexed-carboplatin combination as first-line therapy in patients with advanced nonsmall cell lung cancer...
  21. ncbi request reprint Akt activation correlates with adverse outcome in tongue cancer
    Erminia Massarelli
    Department of Head and Neck Thoracic Medical Oncology, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:2430-6. 2005
    ..This study evaluated the role of Akt in previously untreated preneoplastic lesions of oral cavity and invasive tongue carcinoma on patient outcome and cancer development...
  22. ncbi request reprint Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
    ..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer...
  23. ncbi request reprint Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer
    Julie G Izzo
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Natl Cancer Inst 95:198-205. 2003
    ....
  24. ncbi request reprint Chemoprevention of head and neck cancer
    Katrina Y Glover
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA
    Curr Oncol Rep 5:152-7. 2003
    ..This article reviews the field of chemoprevention and recent advances in molecular epidemiology and genetics. Current clinical trials are described...
  25. ncbi request reprint Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer
    Faye M Johnson
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:17-21. 2003
    ..Patients generally tolerated the weekly alternating chemotherapy with irinotecan/cisplatin and etoposide/cisplatin well, and this combination possessed significant antitumor activity in small-cell lung cancer...
  26. ncbi request reprint Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2214-23. 2003
    ....
  27. ncbi request reprint Focus on head and neck cancer
    Li Mao
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA
    Cancer Cell 5:311-6. 2004
  28. ncbi request reprint Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:952-9. 2005
    ..The authors investigated p27 and E-cadherin protein expression in the early stages of head and neck tumorigenesis and evaluated their predictive roles individually and in association with carcinogenesis...
  29. doi request reprint High-dose fenretinide in oral leukoplakia
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:22-6. 2009
    ..This result is consistent with our clinical finding that high-dose fenretinide did not improve on the historical response rate of lower-dose fenretinide in our previous oral leukoplakia trial...
  30. ncbi request reprint Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia
    James L Mulshine
    Intervention Section, Cell and Cancer Biology Branch, Department of Pathology and Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1906, USA
    Clin Cancer Res 10:1565-73. 2004
    ..This trial evaluated if a topically delivered oral rinse containing ketorolac was as safe as and more effective than oral rinse alone in reducing the area of oral leukoplakia...
  31. ncbi request reprint An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia
    Charles M Rudin
    Medical Center, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA
    J Clin Oncol 21:4546-52. 2003
    ..The current study sought to establish the feasibility and activity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histologically dysplastic lesions of the oral mucosa...